Envoy Medical SEC Filings

Envoy Medical, Inc. files a prospectus supplement describing a securities offering and related risk factors. The company lists numerous operational and industry risks including regulatory uncertainty for medical devices, potential product design changes, supplier and manufacturing disruptions, reimbursement policy shifts, competition and alternative therapies, capital needs and financing availability, intellectual property risks, legal and regulatory proceedings, and catastrophic events. The prospectus also details planned uses of proceeds to advance Acclaim CI clinical development, pursue additional regulatory approvals, build commercial infrastructure, rely on third-party suppliers, expand intellectual property, and hire personnel. The filing discloses potential dilution from various warrants, options and convertible preferred shares (examples: 14,166,666 Public Warrant shares; 3,104,511 Meteora Warrant shares; 3,588,406 shares on conversion of Series A Preferred; and equity incentive plan options). It incorporates multiple prior reports by reference.

Envoy Medical, Inc. disclosed that it and certain related parties entered into a Voting and Warrant Extension Agreement dated September 4, 2025. The agreement extends the expiration date of warrants held by GAT Funding, LLC and related Taylor parties to December 31, 2028. Prior to the extension those warrants had staggered expirations between February 27, 2026 and June 26, 2027.

The filing identifies Glen A. Taylor and affiliated entities as the warrant holders and notes Mr. Taylor directly or indirectly owns approximately 47.8% of the Company’s outstanding Class A Common Stock. The document is filed on Form 8-K and includes the Voting and Warrant Extension Agreement as an exhibit.

Envoy Medical, Inc. (COCH) insider filing by Glen A. Taylor reports multiple warrant amendments and related ownership disclosures. The filing shows Mr. Taylor as a director and >10% owner through direct holdings and indirect interests via Taylor Sports Group and GAT Funding, LLC. He disposed of 2,953,607 Class A shares and retains indirect and direct beneficial ownership positions: 2,526,058 shares indirectly and 4,810,384 shares indirectly via GAT Funding, LLC. The Form 4 documents cancellation of several "old" warrants and issuance of replacement warrants on 09/04/2025; replacement warrants are fully exercisable and, for several series, extend exercise expirations to 12/31/2028 while some near-term cancelled warrants show zero remaining post-transaction balances.

Envoy Medical, Inc. filed an 8-K reporting the satisfaction of promissory notes between the company and GAT Funding, LLC, effective August 25, 2025. The filing references termination of a material definitive agreement and notes related disclosure items for director or officer changes without providing specific names or details in the text provided.

The filing lists the company's securities (Class A Common Stock, COCH; Redeemable Warrants, COCHW) and attaches a press release dated August 26, 2025. The document is signed by Brent T. Lucas, Chief Executive Officer.

Alta Partners LLC filed a Schedule 13G reporting beneficial ownership of 1,944,139 shares of Envoy Medical, Inc. Class A common stock (shares issuable upon exercise of warrants), representing 8.25% of the class. Alta Partners reports sole voting and dispositive power over these shares and certifies the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.